195 related articles for article (PubMed ID: 37616519)
1. Current Treatments in Mantle Cell Lymphoma.
Avyakta Kallam Md ; Vose JM
Oncology (Williston Park); 2023 Aug; 37(8):326-333. PubMed ID: 37616519
[TBL] [Abstract][Full Text] [Related]
2. New Directions for Mantle Cell Lymphoma in 2022.
Kumar A; Eyre TA; Lewis KL; Thompson MC; Cheah CY
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-15. PubMed ID: 35561299
[TBL] [Abstract][Full Text] [Related]
3. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
[TBL] [Abstract][Full Text] [Related]
4. High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.
Nabrinsky E; Danilov AV; Koller PB
Curr Hematol Malig Rep; 2021 Feb; 16(1):8-18. PubMed ID: 33507515
[TBL] [Abstract][Full Text] [Related]
5. Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma.
Lymphoma Research Foundation LRF
Oncology (Williston Park); 2024 Feb; 38(2):51-67. PubMed ID: 38421601
[TBL] [Abstract][Full Text] [Related]
6. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.
Jain P; Wang ML
Am J Hematol; 2022 May; 97(5):638-656. PubMed ID: 35266562
[TBL] [Abstract][Full Text] [Related]
7. ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.
Abramson JS; Ghosh N; Smith SM
Am Soc Clin Oncol Educ Book; 2020 May; 40():302-313. PubMed ID: 32421455
[TBL] [Abstract][Full Text] [Related]
8. Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells.
Wallace D; Reagan PM
Drugs; 2021 Apr; 81(6):669-684. PubMed ID: 33783717
[TBL] [Abstract][Full Text] [Related]
9. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic options for relapsed/refractory mantle cell lymphoma.
Eyre TA; Cheah CY; Wang ML
Blood; 2022 Feb; 139(5):666-677. PubMed ID: 34679161
[TBL] [Abstract][Full Text] [Related]
11. Advances and issues in mantle cell lymphoma research: report of the 2014 Mantle Cell Lymphoma Consortium Workshop.
Kahl BS; Gordon LI; Dreyling M; Gascoyne RD; Sotomayor EM
Leuk Lymphoma; 2015; 56(9):2505-11. PubMed ID: 25944379
[TBL] [Abstract][Full Text] [Related]
12. Mantle cell lymphoma: insights into therapeutic targets at the preclinical level.
Klener P
Expert Opin Ther Targets; 2020 Oct; 24(10):1029-1045. PubMed ID: 32842810
[TBL] [Abstract][Full Text] [Related]
13. CAR T-Cell therapy for the management of mantle cell lymphoma.
Huang Z; Chavda VP; Bezbaruah R; Dhamne H; Yang DH; Zhao HB
Mol Cancer; 2023 Mar; 22(1):67. PubMed ID: 37004047
[TBL] [Abstract][Full Text] [Related]
14. Mantle cell lymphoma-Update on molecular biology, prognostication and treatment approaches.
Silkenstedt E; Dreyling M
Hematol Oncol; 2023 Jun; 41 Suppl 1():36-42. PubMed ID: 37294961
[TBL] [Abstract][Full Text] [Related]
15. What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?
McCulloch R; Eyre TA; Rule S
Hematol Oncol Clin North Am; 2020 Oct; 34(5):923-939. PubMed ID: 32861287
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma.
Li P; Dong N; Zeng Y; Liu J; Tang X; Wang J; Zhang W; Ye S; Zhou L; Chang AH; Liang A
Front Med; 2020 Dec; 14(6):811-815. PubMed ID: 32651937
[TBL] [Abstract][Full Text] [Related]
17. Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop.
Williams ME; Connors JM; Dreyling MH; Gascoyne RD; Kahl BS; Leonard JP; Press OW; Wilson WH
Leuk Lymphoma; 2011 Jan; 52(1):24-33. PubMed ID: 21133727
[TBL] [Abstract][Full Text] [Related]
18. Molecular profiling and management of mantle cell lymphoma.
Ruan J
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):30-40. PubMed ID: 31808882
[TBL] [Abstract][Full Text] [Related]
19. Current trials for frontline therapy of mantle cell lymphoma.
Steiner RE; Romaguera J; Wang M
J Hematol Oncol; 2018 Jan; 11(1):13. PubMed ID: 29374487
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in mantle cell lymphoma: report of the 2013 Mantle Cell Lymphoma Consortium Workshop.
Gordon LI; Bernstein SH; Jares P; Kahl BS; Witzig TE; Dreyling M
Leuk Lymphoma; 2014 Oct; 55(10):2262-70. PubMed ID: 24512319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]